Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIGHT: HLA Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation
NCT06809712Phase 1Recruiting
- Start
- Aug 2022
- Primary completion
- Oct 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of busulfan, cyclophosphamide, fludarabine and semustine in hematological malignancy. Primary endpoint: Overall survival at 1 year. Started Aug 2022; status: recruiting.
02
Drugs
busulfancyclophosphamidefludarabinesemustine
03
Conditions
hematological malignancy
Beyond the preview
Go deeper on NCT06809712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809712.